Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Mometasone Furoate

Criteria

Inclusion Criteria:

• Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis.

Exclusion Criteria:

• Patients with an infection for which there is no effective antimicrobial drug or systemic fungal infection [symptoms may exacerbate]

• Patients with a history of hypersensitivity to any ingredient of this drug